FGL

FGL, a 15-amino-acid synthetic peptide corresponding to the NCAM binding site for fibroblast growth factor receptor 1 (FGFR1), was administered intracerebroventricularly to rats immediately after training and produced a long-lasting facilitation of memory in both contextual fear conditioning and Morris water maze paradigms. In primary hippocampal neuron cultures, FGL enhanced presynaptic function via FGFR1 activation and promoted synapse formation, as shown by increased synaptophysin-positive puncta and augmented neurotransmitter release. The authors conclude that increased synaptic transmission efficacy and formation of new synapses likely mediate the peptide's cognition-enhancing effects, providing the first evidence that pharmacologically mimicking NCAM function facilitates memory.

Scientists gave rats a small lab-made peptide called FGL, which copies part of a natural brain molecule (NCAM) that helps brain cells connect. Rats treated with FGL remembered learned tasks better, and the improvement lasted for weeks. In dishes of brain cells, the peptide helped neurons form more connections and communicate more effectively, suggesting it aids memory by strengthening and building synapses. Note: this is an early rodent and cell-culture study, not evidence in humans.

In aged rats and in glial cell cultures, the NCAM-derived peptide FGL attenuated markers of neuroinflammation, reducing pro-inflammatory signaling associated with hippocampal aging. The anti-inflammatory action was linked to modulation of insulin-like growth factor-1 (IGF-1) and interferon-gamma (IFN-gamma), with FGL promoting IGF-1-associated signaling that inhibits microglial activation. These findings indicate that FGL can dampen age- and IFN-gamma-driven glial activation and the accompanying cytokine production, supporting a mechanistic role in restraining neuroinflammatory processes.

As brains age, their immune cells (microglia) become overactive and cause harmful inflammation. This study found that the FGL peptide calmed this inflammation in aged rats and in brain-cell cultures, partly by boosting a protective growth factor (IGF-1) and countering an inflammatory signal (interferon-gamma). This suggests FGL may help protect the aging brain from damaging inflammation, though the work was done only in rats and cells, not people.

Chronic administration of FGL to aged rats reduced microglial and astrocytic activation in the hippocampus, as assessed by immunohistochemical and morphometric analysis of glial markers. The peptide attenuated the age-related increase in activated glia and associated neuroinflammatory changes, consistent with a shift toward a less inflammatory glial phenotype. The data reinforce the proposal that FGL exerts neuroprotective effects in the aged brain by limiting chronic glial activation, a driver of age-related cognitive and synaptic decline.

In older rats, the brain's support and immune cells become chronically inflamed, which can harm memory. Treating aged rats with the FGL peptide reduced this over-activation of those cells in the memory-related hippocampus. The results add to evidence that FGL may protect the aging brain by quieting harmful inflammation, but this remains a rodent finding with no human data.